News
Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with…
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…
The US Food and Drug Administration (FDA) has approved inotersen (Tegsedi, Akcea Therapeutics and Ionis Pharmaceuticals) for the treatment of polyneuropathy (PN) in…
A new hereditary ATTR (hATTR) amyloidosis treatment, inotersen, an investigational antisense drug, may not be far from a US Food and Drug Administration (FDA)…
Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it.
"I had so many symptoms, and I really…
Updated research regarding the ANDROMEDA study presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicated the…
Amyloidosis is a disorder in which certain proteins abnormally change their shape in a process called "misfolding." The misfolded proteins accumulate together and…
Cardiac amyloidosis, traditionally considered a rare and dire disease, is receiving increasing attention as sophisticated diagnostics are identifying more patients…
Although most patients with familial amyloid polyneuropathy (FAP) who undergo liver transplant will require a pacemaker, implanting the device before the transplant…
AL amyloidosis is a rare condition caused when bone marrow produces abnormal antibodies that can't be broken down and are deposited in tissues, interfering with…